Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04251520 · ClinicalTrials.gov registry record · NA
The Role of the Pharmacist and Pharmacogenomics in the Care of Seriously Ill Patients
A NA study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT04251520: Clinical Trial NA study, sponsored by Mayo Clinic.
NCT04251520 is a NA study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04251520, a NA study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
Researchers are trying to learn more about how pharmacists and pharmacogenomic testing can help care providers improve control of symptoms and quality of life in seriously ill patients.
Interventions
- DIAGNOSTIC_TEST Pharmacogenomics testing
- OTHER Pharmacist review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-04-15 |
| Est. Completion | 2022-01-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04251520
The ClinicalTrials.gov registry entry for NCT04251520 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pharmacogenomics testing is the first listed.
NCT04251520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04251520 about?
NCT04251520 is a clinical study titled "The Role of the Pharmacist and Pharmacogenomics in the Care of Seriously Ill Patients". Researchers are trying to learn more about how pharmacists and pharmacogenomic testing can help care providers improve control of symptoms and quality of life in seriously ill patients.
What is the current status of trial NCT04251520?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2021-04-15. Estimated completion is 2022-01-12.
What interventions are being tested in trial NCT04251520?
The interventions under investigation include: Pharmacogenomics testing (DIAGNOSTIC_TEST), Pharmacist review (OTHER).
Who is sponsoring clinical trial NCT04251520?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.